Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
330 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04686305 | Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC(DL03) | recruiting | Phase 1 | 304 | AstraZenecaINDUSTRY | 19 | Apr 13, 2026 | clinicaltrials |
| NCT05203172 | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | recruiting | Phase 4 | 46 | PfizerINDUSTRY | 17 | Apr 7, 2026 |
| clinicaltrials |
| NCT05047094 | Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC | recruiting | N/A | 48 | Alpha Tau Medical LTD.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05304377 | A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia(CML) | recruiting | Phase 1 | 250 | Enliven TherapeuticsINDUSTRY | 14 | Apr 1, 2026 | clinicaltrials |
| NCT06093672 | Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera(GIV-IN-PV) | recruiting | Phase 3 | 220 | ItalfarmacoINDUSTRY | 16 | Mar 25, 2026 | clinicaltrials |
| NCT06630806 | A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma | recruiting | Phase 1 | 87 | SanofiINDUSTRY | 7 | Mar 25, 2026 | clinicaltrials |
| NCT03590171 | International Study for Treatment of High Risk Childhood Relapsed ALL 2010 | recruiting | Phase 2 | 250 | Charite University, Berlin, GermanyOTHER | 15 | Mar 17, 2026 | clinicaltrials |
| NCT05730036 | A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma(LINKER-MM3) | recruiting | Phase 3 | 410 | Regeneron PharmaceuticalsINDUSTRY | 18 | Mar 6, 2026 | clinicaltrials |
| NCT07110584 | Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 235 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 2 | Mar 5, 2026 | clinicaltrials |
| NCT06446882 | Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer(DEFINITIVE) | recruiting | N/A | 304 | Fundacio Clinic BarcelonaOTHER | 5 | Feb 20, 2026 | clinicaltrials |
| NCT03463954 | Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors | recruiting | N/A | 122 | Novian Health Inc.INDUSTRY | 5 | Feb 19, 2026 | clinicaltrials |
| NCT06830759 | Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma(EpcoReal) | recruiting | — | 700 | AbbVieINDUSTRY | 13 | Feb 17, 2026 | clinicaltrials |
| NCT04895436 | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)(ReVenG) | recruiting | Phase 2 | 75 | AbbVieINDUSTRY | 11 | Feb 9, 2026 | clinicaltrials |
| NCT07384013 | Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs | recruiting | N/A | 30 | Rambam Health Care CampusOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT04414475 | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. | recruiting | Phase 2 | 127 | Karyopharm Therapeutics IncINDUSTRY | 2 | Feb 2, 2026 | clinicaltrials |
| NCT07135466 | A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies | recruiting | Phase 1 / Phase 2 | 50 | Sheba Medical CenterOTHER_GOV | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05345613 | Tranexamic Acid During Colonic Endoscopic Resection Procedures | recruiting | Phase 4 | 200 | Assaf-Harofeh Medical CenterOTHER_GOV | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07333430 | Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 | 60 | Hadassah Medical OrganizationOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07327021 | MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC(NOGA) | recruiting | Phase 2 | 54 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jan 8, 2026 | clinicaltrials |
| NCT03889899 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia. | recruiting | N/A | 30 | Alpha Tau Medical LTD.INDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07224451 | Liquid Biopsy Following BBB Disruption Using Barrier Disrupting Fields in Patients Undergoing Spine Surgery(BDF002) | recruiting | N/A | 20 | Sheba Medical CenterOTHER_GOV | 1 | Nov 4, 2025 | clinicaltrials |
| NCT06174987 | A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) | recruiting | Phase 3 | 50 | Daiichi SankyoINDUSTRY | 12 | Oct 15, 2025 | clinicaltrials |
| NCT07208240 | Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST Trial. | recruiting | Phase 1 / Phase 2 | 20 | Rabin Medical CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT00722228 | Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors | recruiting | Phase 1 / Phase 2 | 50 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT01898039 | Modified Vaccine for High Risk or Low Residual Melanoma Patients | recruiting | Phase 1 / Phase 2 | 50 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05658640 | HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies(HEM-iSMART D) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 15 | Sep 16, 2025 | clinicaltrials |
| NCT05745714 | HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART C) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 14 | Sep 16, 2025 | clinicaltrials |
| NCT05751044 | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART B) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 14 | Sep 16, 2025 | clinicaltrials |
| NCT03053193 | MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles(FLEX) | recruiting | — | 30,000 | AgendiaINDUSTRY | 4 | Aug 20, 2025 | clinicaltrials |
| NCT07131163 | Real World Stage II-III NSCLC Patients Receiving Neoadjuvant Chemo-immunotherapy and no Surgical Resection(NoSurgery) | recruiting | — | 60 | Sheba Medical CenterOTHER_GOV | 1 | Aug 20, 2025 | clinicaltrials |
| NCT05833165 | Feasibility of Integrating Homeopathic Approach in a Comprehensive Cancer Center | recruiting | — | 250 | Rambam Health Care CampusOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT05992363 | Tandem Polyurethane Stents Compared to Single Silicone Stent for Malignant Ureteral Obstruction(TSTENT) | recruiting | N/A | 106 | Rabin Medical CenterOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT06940388 | Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.(TOTAL) | recruiting | Phase 2 | 134 | brenner baruchOTHER | 2 | Jul 24, 2025 | clinicaltrials |
| NCT05909618 | Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases(14) | recruiting | Phase 2 | 33 | Sheba Medical CenterOTHER_GOV | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05560659 | Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy(POPSTAR II) | recruiting | Phase 2 | 92 | Peter MacCallum Cancer Centre, AustraliaOTHER | 2 | Jul 11, 2025 | clinicaltrials |
| NCT06839144 | Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression(OC-POP-PT) | recruiting | Phase 2 | 60 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jul 11, 2025 | clinicaltrials |
| NCT06971380 | Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis | recruiting | Phase 2 | 180 | Polina StepenskyOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT05882175 | Prospective Validation of the OHI Index(HLH) | recruiting | — | 300 | Meir Medical CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06963307 | Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer(LumenDx) | recruiting | — | 300 | JaxBio LtdINDUSTRY | 1 | May 9, 2025 | clinicaltrials |
| NCT05201404 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis(LIVERATION) | recruiting | Phase 3 | 471 | Can-Fite BioPharmaINDUSTRY | 9 | Apr 29, 2025 | clinicaltrials |
| NCT06940349 | Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors(COPS-01) | recruiting | Phase 1 / Phase 2 | 100 | Rabin Medical CenterOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT04775485 | A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors(FIREFLY-1) | recruiting | Phase 2 | 141 | Day One Biopharmaceuticals, Inc.INDUSTRY | 11 | Apr 10, 2025 | clinicaltrials |
| NCT03643276 | Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 | recruiting | Phase 3 | 5,000 | Martin SchrappeOTHER | 8 | Apr 6, 2025 | clinicaltrials |
| NCT06889467 | Liquid Biopsy Assay of EBUS-TBNA Supernatant Fluid for Diagnosing Lung Cancer | recruiting | — | 10 | Barzilai Medical CenterOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT03818503 | E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe(E²-RADIatE) | recruiting | — | 2,000 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 14 | Mar 21, 2025 | clinicaltrials |
| NCT05640700 | Vaginal Microbiome and HPV Pre-malignant and Cervical Dysplasia | recruiting | — | 90 | Hadassah Medical OrganizationOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06202118 | A Study of Diffusing Alpha Radiation Therapy for Patients With Breast Carcinoma in Frail or Elderly Patients. | recruiting | N/A | 10 | Alpha Tau Medical LTD.INDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials